- $16.19m
- -$40.86m
- $0.19m
aTyr Pharma up as dosing starts in lung disease therapy trial
Brief: aTyr Pharma Receives FDA Fast Track Designation For Efzofitimod For Treatment Of Systemic Sclerosis-Associated Interstitial Lung Disease
Brief: aTyr Pharma To Present Poster At European Respiratory Society International Congress 2022
U.S. RESEARCH ROUNDUP- Aptinyx, Rapid Micro Biosystems, Trinet Group
aTyr Pharma Inc reports results for the quarter ended in June - Earnings Summary
Brief: aTyr Pharma Announces Q2 2022 Results And Provides Corporate Update
aTyr Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Warby Parker, NV5 Global, Absci
U.S. STOCKS ON THE MOVE-Cyclacel, Major U.S. banks, Gold miners
U.S. STOCKS ON THE MOVE-Energy firms, WeWork, aTyr Pharma
aTyr Pharma up on FDA's 'fast track' tag for lung disease therapy
Brief: aTyr Pharma Announces Fgfr4 As Receptor Target For Aars Trna Synthetase Fragment
Brief: aTyr Pharma Announces Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis
aTyr Pharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: ATyr Pharma Posts Quarterly Loss Per Share $0.44
aTyr Pharma Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: aTyr Pharma Reports FDA Orphan Drug Designation for Efzofitimod for Treatment of Systemic Sclerosis
Brief: ATyr Pharma To Present Clinical Data For Efzofitimod
Brief: aTYR Pharma Files For Mixed Shelf Of Up To $200 Million